Johnson & Johnson Operating Expenses 2010-2024 | JNJ
Johnson & Johnson annual/quarterly operating expenses history and growth rate from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
- Johnson & Johnson operating expenses for the quarter ending March 31, 2024 were $14.943B, a 41.36% decline year-over-year.
- Johnson & Johnson operating expenses for the twelve months ending March 31, 2024 were $59.557B, a 13.12% decline year-over-year.
- Johnson & Johnson annual operating expenses for 2023 were $70.097B, a 15.61% increase from 2022.
- Johnson & Johnson annual operating expenses for 2022 were $60.631B, a 1.79% increase from 2021.
- Johnson & Johnson annual operating expenses for 2021 were $59.562B, a 9.87% decline from 2020.
Johnson & Johnson Annual Operating Expenses
(Millions of US $) |
| 2023 |
$70,097 |
| 2022 |
$60,631 |
| 2021 |
$59,562 |
| 2020 |
$66,087 |
| 2019 |
$64,731 |
| 2018 |
$63,582 |
| 2017 |
$58,777 |
| 2016 |
$52,087 |
| 2015 |
$50,878 |
| 2014 |
$53,768 |
| 2013 |
$55,841 |
| 2012 |
$53,449 |
| 2011 |
$52,669 |
| 2010 |
$44,640 |
| 2009 |
$46,142 |
Johnson & Johnson Quarterly Operating Expenses
(Millions of US $) |
| 2024-03-31 |
$14,943 |
| 2023-12-31 |
$9,712 |
| 2023-09-30 |
$16,134 |
| 2023-06-30 |
$18,768 |
| 2023-03-31 |
$25,483 |
| 2022-12-31 |
$10,063 |
| 2022-09-30 |
$14,824 |
| 2022-06-30 |
$18,180 |
| 2022-03-31 |
$17,564 |
| 2021-12-31 |
$8,531 |
| 2021-09-30 |
$19,489 |
| 2021-06-30 |
$16,650 |
| 2021-03-31 |
$14,892 |
| 2020-12-31 |
$20,828 |
| 2020-09-30 |
$16,681 |
| 2020-06-30 |
$14,396 |
| 2020-03-31 |
$14,182 |
| 2019-12-31 |
$16,529 |
| 2019-09-30 |
$19,082 |
| 2019-06-30 |
$13,521 |
| 2019-03-31 |
$15,599 |
| 2018-12-31 |
$17,272 |
| 2018-09-30 |
$15,925 |
| 2018-06-30 |
$15,857 |
| 2018-03-31 |
$14,528 |
| 2017-12-31 |
$17,635 |
| 2017-09-30 |
$14,860 |
| 2017-06-30 |
$14,091 |
| 2017-03-31 |
$12,191 |
| 2016-12-31 |
$13,782 |
| 2016-09-30 |
$12,539 |
| 2016-06-30 |
$13,578 |
| 2016-03-31 |
$12,188 |
| 2015-12-31 |
$14,053 |
| 2015-09-30 |
$12,980 |
| 2015-06-30 |
$12,046 |
| 2015-03-31 |
$11,799 |
| 2014-12-31 |
$15,551 |
| 2014-09-30 |
$11,657 |
| 2014-06-30 |
$13,869 |
| 2014-03-31 |
$12,691 |
| 2013-12-31 |
$15,605 |
| 2013-09-30 |
$13,908 |
| 2013-06-30 |
$13,084 |
| 2013-03-31 |
$13,244 |
| 2012-12-31 |
$14,458 |
| 2012-09-30 |
$13,457 |
| 2012-06-30 |
$14,440 |
| 2012-03-31 |
$11,094 |
| 2011-12-31 |
$15,937 |
| 2011-09-30 |
$11,894 |
| 2011-06-30 |
$13,175 |
| 2011-03-31 |
$11,663 |
| 2010-12-31 |
$13,416 |
| 2010-09-30 |
$10,763 |
| 2010-06-30 |
$11,110 |
| 2010-03-31 |
$9,351 |
| 2009-12-31 |
$13,947 |
| 2009-09-30 |
$10,836 |
| 2009-06-30 |
$10,976 |
| 2009-03-31 |
$10,383 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$356.431B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
